Company News: Express Scripts, Medco, Roche, Eli Lilly
Roche said sales were down 4% and 2% for the second quarter and first six months, respectively. Accounting for some of this decline were decreases in sales of cancer drug Avastin (down 7%) and leukemia med Rituxan (down 3%). Diagnostics sales were also down about 2%.
Eli Lilly reported second-quarter revenue up 9% to $6.3 billion, beating analyst consensus by 4%. Lilly did not include any significant pipeline updates in the Q2 report.